CRBU trades 1367.6% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CRBU achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Caribou Biosciences, Inc. (CRBU) has a Wall Street consensus price target of $5.00, based on estimates from 9 covering analysts. With the stock currently trading at $0.34, this represents a potential upside of +1367.6%. The company has a market capitalization of $34M.
Analyst price targets range from a low of $3.00 to a high of $7.00, representing a 80% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRBU trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +0.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EDITEditas Medicine, Inc. | $281M | $1.83 | $5.50 | +201.4% | Buy | — | 26 |
BEAMBeam Therapeutics Inc. | $2.1B | $20.65 | $66.00 | +219.6% | Buy | — | 28 |
NTLAIntellia Therapeutics, Inc. | $1.1B | $9.78 | $20.71 | +111.8% | Buy | — | 39 |
CRSPCRISPR Therapeutics AG | $3.9B | $40.15 | $64.14 | +59.8% | Buy | — | 38 |
FATEFate Therapeutics, Inc. | $119M | $1.02 | $5.63 | +452.0% | Buy | — | 31 |
ALLOAllogene Therapeutics, Inc. | $257M | $0.74 | $26.53 | +3465.4% | Buy | — | 30 |
ILMNIllumina, Inc. | $30.7B | $202.61 | $252.73 | +24.7% | Buy | 37.4x | 50 |
TMOThermo Fisher Scientific Inc. | $255.2B | $686.79 | $694.27 | +1.1% | Buy | 27.2x | 43 |
PACBPacific Biosciences of California, Inc. | $565M | $1.82 | $1.93 | +6.0% | Buy | — | 18 |
TWSTTwist Bioscience Corporation | $7.0B | $112.00 | $153.70 | +37.2% | Buy | — | 15 |
Quick answers to the most common questions about buying CRBU stock.
The consensus Wall Street price target for CRBU is $5, representing 1367.6% upside from the current price of $0.3407. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CRBU has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 1367.6% upside from current levels.
CRBU's current price is $0.3407 with a consensus target of $5 (1367.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for CRBU, while the most conservative target is $3. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
CRBU is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRBU stock forecast based on 9 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $3 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CRBU, with a "Buy" consensus rating and $5 price target (1367.6% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRBU analyst price targets range from $3 to $7, a 80% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.